Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

A satirical X post saying the three major insulin manufacturers in the United States had announced 2,000%-3,000% price ...

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a shift toward ...

Despite online claims, President Donald Trump’s executive orders did not include removing Medicare’s $35 monthly ...

With every new year comes reflection and resolutions. But as we go to press well into January, it is worth a reminder that studies show nearly 90% ...